Drug Search Results
More Filters [+]

Calaspargase pegol

Alternative Names: calaspargase pegol, calaspargase pegol-mknl, asparlas
Latest Update: 2024-06-26
Latest Update Note: Clinical Trial Update

Product Description

A drug used with other drugs to treat acute lymphoblastic leukemia in children and young adults aged 1 month to 21 years. It is also being studied in the treatment of other types of cancer. Calaspargase pegol is made up of the enzyme L-asparaginase that is linked to a substance called SC-PEG, which makes the drug stay in the body longer. L-asparaginase comes from the bacterium E. coli and breaks down the amino acid asparagine. This may stop the growth of cancer cells that need asparagine to grow. Calaspargase pegol is a type of protein synthesis inhibitor. Also called Asparlas, EZN-2285, and SC-PEG E. coli L-asparaginase. (Sourced from: https://www.cancer.gov/publications/dictionaries/cancer-terms/def/calaspargase-pegol)

Mechanisms of Action: L-Asparagine Converter

Novel Mechanism: No

Modality: Peptide/Protein

Route of Administration: Intravenous,Subcutaneous

FDA Designation: None *

Approval Status: Approved

Approved Countries: United States

Approved Indications: Acute Leukemia | Acute Lymphoid Leukemia | Leukemia | Lymphoid Leukemia

Known Adverse Events: Pancreatitis

Company: St. Jude Children's Research Hospital
Company Location:
Company CEO:
Additonal Commercial Interests: None

Clinical Description

Map of Global Clinical Trials for Calaspargase pegol

Countries in Clinic: Australia, United States

Active Clinical Trial Count: 3

Highest Development Phases

Phase 3: Acute Lymphoid Leukemia|Precursor Cell Lymphoblastic Leukemia-Lymphoma

Phase 1: Adenocarcinoma|Pancreatic Cancer

Trial

Phase

Trial Status

Disease

Primary Completion Date

Probability of Success

TOT17

P3

Active, not recruiting

Acute Lymphoid Leukemia|Precursor Cell Lymphoblastic Leukemia-Lymphoma

2026-09-30

MCC-21213

P1

Recruiting

Precursor Cell Lymphoblastic Leukemia-Lymphoma|Acute Lymphoid Leukemia

2025-05-01

STUDY00022141

P1

Recruiting

Adenocarcinoma|Pancreatic Cancer

2024-12-16

Recent News Events